9 completed, 1 terminated. 6 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
Follow VGX-3100: new trials by email Literature Review of VGX-3100 trials Research Report on VGX-3100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) VGX-3100, Matched Placebo, CELLECTRA™-5PSP - Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Completed | Inovio Pharmaceuticals | 203 | 2019-02-28 | 2024-10-17 |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis - Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia | Phase 2 | Completed | AIDS Malignancy Consortium | 44 | 2018-09-21 | 2026-07-08 |
| VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 VGX-3100, CELLECTRA™ 5PSP - Anal Neoplasm | Phase 2 | Completed | Inovio Pharmaceuticals | 23 | 2018-05-15 | 2023-07-14 |
| Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000 - Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia | Phase 2 | Completed | Inovio Pharmaceuticals | 33 | 2017-08-31 | 2023-08-25 |
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) VGX-3100, Placebo, Electroporation (EP) - Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Completed | Inovio Pharmaceuticals | 201 | 2017-06-28 | 2023-07-27 |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma INO-3112, CELLECTRA™-5P - Head and Neck Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 22 | 2014-08-13 | 2021-01-22 |
| A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer INO-3112, CELLECTRA™-5P - Cervical Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 10 | 2014-06-06 | 2021-02-21 |
| Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 VGX-3100 - Human Papillomavirus (HPV) | Phase 1 | Completed | Inovio Pharmaceuticals | 14 | 2010-07-01 | 2018-08-10 |
| Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 VGX-3100 - Papillomavirus Infections | Phase 1 | Completed | Inovio Pharmaceuticals | 18 | 2008-05-01 | 2017-09-13 |
Squamous Intraepithelial Lesions (4) · Uterine Cervical Neoplasms (4) · Anus Neoplasms (2) · Uterine Cervical Dysplasia (2) · Anal Canal Carcinoma (1) · HIV Seropositivity (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Papillomavirus Infections (1) · Penile Neoplasms (1) · Recurrence (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Inovio Pharmaceuticals (8) · AIDS Malignancy Consortium (1) · M.D. Anderson Cancer Center (1)
United States (10) · Puerto Rico (5) · Argentina (2) · Estonia (2) · Finland (2) · Lithuania (2) · Poland (2) · South Africa (2) · Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · Germany (1) · Italy (1) · Mexico (1)
Jeffrey Skolnik, MD (6) · Javier Morales, MD (2) · John Sunyecz, MD (2) · Robert Parker, MD (2) · Christina Chu, MD (1) · Michael M Frumovitz (1)
2016 (1), 2018 (1), UM1CA121947 (1)